FMS - Fresenius sees GLP-1 drugs having neutral impact on its business: report
2023-10-12 15:39:22 ET
More on Fresenius Medical Care
- Fresenius Medical Care: Don't Let The Ozempic Kidney Failure Scare You Off
- Fresenius Medical Care AG & Co. KGaA (FMS) Q2 2023 Earnings Call Transcript
- Fresenius Medical Care: Heads Don't Roll - They Run
- Dialysis stocks decline again as Novo Nordisk hits 52-week high
- Dialysis stocks tumble on Ozempic kidney failure study news (update)
For further details see:
Fresenius sees GLP-1 drugs having neutral impact on its business: report